O besity represents our largest preventable healthcare problem with the majority of Americans currently categorized as overweight or obese. [1] [2] [3] The American Medical
Association labeled obesity as a disease highlighting its critical negative impact on public health, 4 and over two thirds of deaths related to obesity worldwide are from cardiovascular causes. 5 Excess fat, particularly accumulation of intra-abdominal visceral fat, has been linked to lipotoxicity, adipose tissue dysfunction, and inflammation that are implicated in the development of insulin resistance, endothelial dysfunction, and cardiovascular disease; [6] [7] [8] [9] [10] however, pathophysiological mechanisms are incompletely understood.
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The endothelium plays a critical role in vascular homeostasis and many of its functions are governed by the basal and stimulated release of endothelium-derived nitric oxide (NO) that maintains arterial tone, inhibits inflammation, promotes fibrinolysis, and modulates reparative angiogenesis. [13] [14] [15] Studies have shown that insulin resistance not only disrupts metabolic pathways and organs, but also adversely impacts the vasculature. 13 Insulin normally regulates blood flow through activation of endothelial NO synthase (eNOS) by binding to its receptor and subsequent activation of eNOS via PI3-K/Akt. 16 Defective insulin signaling leads to vascular inflammation, vasoconstriction, plaque progression, and ischemia. Endothelium-specific deletion of the insulin receptor in animal models causes atherosclerosis. 17, 18 Thus, understanding signaling pathways that regulate endothelial function are pivotal for atherosclerosis initiation and progression. FSP27 (Fat-specific protein 27) is a lipid dropletassociated protein that regulates lipolysis and insulin sensitivity in adipocytes, and plays a key role in governing whole body metabolism. [19] [20] [21] [22] Experimental models showed that FSP27 deletion augments basal lipolysis and promotes insulin-resistance under high-fat diet conditions. 23 Human genetic mutations of FSP27 are associated with lipodystrophy, hypertriglyceridemia, and insulin-resistance. 24 While cellular actions of FSP27 have been well characterized almost exclusively in adipocytes, we unexpectedly discovered that it is expressed abundantly in human vascular endothelial cells, yet downregulated in association with visceral/central obesity. As lipid storage and breakdown are generally not viewed as a primary function of endothelial cells, we sought to examine whether FSP27 controls vascular phenotype by mechanisms beyond regulation of lipid metabolism and serves as a previously unrecognized regulator of arteriolar vasomotor function and angiogenesis which are important in mechanisms of ischemic cardiovascular disease.
25-27

Materials and Methods
The authors declare that all supporting data are available within the article and its online supplementary files.
Study Subjects
Consecutive obese men and women (body mass index ≥35 kg/m 2 , aged ≥18 years), with severe long-standing obesity undergoing elective bariatric weight-loss surgery at Boston Medical Center were recruited into the study. Subjects with unstable medical conditions or pregnancy were not eligible for bariatric surgery and thus excluded. The study was approved by the Boston University Medical Center Institutional Review Board, and written consent was obtained from all participants.
Anthropometric and Biochemical Measures
During a presurgical outpatient and subsequent postoperative follow-up visit, clinical characteristics including blood pressure, height, weight, and waist circumference were measured, along with recording of cardiovascular risk factors. Fasting blood was taken via an antecubital vein for biochemical parameters including lipids, glucose, insulin, glycosylated hemoglobin, and high-sensitivity C-reactive protein.
Homeostasis model assessment was used as the index of insulin sensitivity. All biochemical analyses were performed by the Boston Medical Center clinical chemistry laboratory.
Adipose Tissue Collection and Percutaneous Adipose Tissue Biopsy
Subcutaneous and visceral adipose tissue were collected intraoperatively from the lower abdominal wall and greater omentum, during planned bariatric surgery, as previously described. [28] [29] [30] Each subject provided one biopsy specimen from the subcutaneous and one specimen from the visceral fat depot. For the longitudinal study component after weight loss, follow-up peri-umbilical subcutaneous fat biopsies were performed percutaneously during a postoperative visit as previously described. 31 Briefly, subjects were placed in supine position with sterile draping of the abdominal region. Local skin anesthesia was performed with subcutaneous lidocaine injection and a small superficial 0.5 cm skin incision made lateral to the umbilicus with a tiny scalpel, which allows for both aspiration of fat using a large-bore cannula and several punch biopsies providing specimens of intact adipose tissue. The anatomic layer and qualitative yield of this procedure is the same as the intra-operative baseline collection. The superficial skin incision was then closed with self-absorbing sutures.
Adipose Vessel Preparation and Assessment of Adipose Arteriolar Function
Adipose tissue specimens were placed immediately in cold HEPES buffer solution, pH 7.51 (American Bioanalytical,
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What Is New?
• FSP27 (Fat-specific protein 27) was thought to be expressed mainly in adipocytes regulating lipolysis; however, we discovered its expression in human endothelial cells where it has additional key functions.
• FSP27 restores vascular insulin sensitivity, vasodilator function, and angiogenesis in dysfunctional microvessels of obese subjects.
• Bariatric surgical weight loss improves metabolism and augments FSP27 expression.
What Are the Clinical Implications?
• FSP27 is a newly identified modulator of vascular function in human disease that exerts regulatory control over vascular endothelial growth factor-A in the human vasculature.
• Obesity-related downregulation of FSP27 may link obesity to cardiometabolic diseases.
Natick, MA). Small adipose arterioles (75-350-lmol/L internal diameter) were carefully removed of surrounding fat and connective tissue. Arterioles were cannulated securely with glass micropipettes within an organ chamber as previously described. [32] [33] [34] The chamber was then mounted onto a stage of an inverted microscope (9200 magnification) and video camera monitor (model VIA-100; Boeckler Instruments, Inc, Tuscon, AZ) for vascular diameter measurements using videomicroscopy. Arterioles were pressure equilibrated in continuously perfused with Krebs buffer aerated with a gas mixture of 5% O 2 , 21% CO 2 and 74% N 2 . The internal arterial diameter of each vessel was initially measured at a steady state followed by administration of endothelin-1 (ET-1, 2910 À6 mol/L; Sigma-Aldrich, St. Louis, MO) to pre-constrict vessels to 50% to 70% of their internal resting diameter. Insulin-mediated, endothelial nitric oxide synthase (eNOS)-dependent vasodilation was determined by measuring the change in diameter in response to insulin (10 À5 mol/L; Sigma-Aldrich) at 5-minute intervals over a time course of 30 minutes in visceral fat microvessels from obese subjects as previously described. 33 Vessels viability and maximum dilator capacity were examined using the endothelial-independent vasodilator papaverine (Pap, 2910 À4 mol/L; SigmaAldrich). To assess the effect of FSP27, isolated microvessels were exposed to vehicle control or 5-lmol/L recombinant FSP27 (rFSP27) in vessel chambers for 60 minutes followed by vasodilation studies. The effect of rFSP27 on insulininduced vasodilation was examined in the presence or absence of eNOS inhibitor Nx-nitro-L-arginine methyl ester (L-NAME, 3910 À4 mol/L, Sigma-Aldrich).
Endothelial Cell Isolation From Adipose Tissue and Insulin Stimulation
Endothelial cells were isolated from human fat as described previously. 29 siRNA-mediated depletion of FSP27 in cultured human aortic endothelial cells (HAEC) was performed according to the manufacturer's protocol for reverse transfection using lipofectamine RNAiMAX (catalogue # 13778030, Thermo Fisher). Briefly, RNA-lipid complexes were made using RNAiMAX and siRNA (scrambled-siRNA and FSP27, 100-nmol/L) in Opti-MEM and added to the culture flask. Trypsinized human aortic endothelial cells (HAEC) were then added and allowed to settle with RNA-lipid complex for 4 hours, EBM-2 media were added, and cells were allowed to grow for 48 hours. For Western immunoblot experiments, cytosolic proteins were collected using protein lysis buffer with protease and phosphate inhibitors and subjected to Western immunoblot. For NO production experiments, cells were starved for 5 hours and stimulated with insulin for 30 minutes and followed by NO measurement protocols.
Endothelial Cell Quantitative Immunofluorescence
We quantified protein FSP27 expression in isolated endothelial cells from subcutaneous and visceral fat. Briefly, fixed samples were rehydrated with 50-mmol/L glycine (SigmaAldrich, St. Louis, MO), permeabilized with 0.1% Triton-X and blocked with 0.5% bovine serum albumin. Slides were incubated overnight at 37°C with primary antibodies against FSP27 (1:250 dilution, catalogue # PA5-30793, Thermo Fisher), and CD31 (1:300 dilution, catalogue # MA3100, Thermo Fisher) to select endothelial cells. We used analogous Alexa Fluor-488 and Alexa Fluor-594 antibodies (1:200 dilution; Invitrogen, Carlsbad, CA) for secondary antibodies. Cells were mounted under glass coverslips with VECTASHIELD (catalogue # H1500, Vector Laboratories, Burlingame, CA) containing DAPI to identify nuclei. Slides were imaged using a fluorescent microscope (920 magnification, Nikon Eclipse TE2000-E) and digital images were captured using a Photometric CoolSnap HQ2 Camera (Photometrics, Tucson, AZ). Exposure time was kept constant and fluorescent intensity (corrected for background fluorescence) was quantified by NIS Elements AR Software (Nikon Instruments Inc, Melville, NY). Fluorescence intensity was quantified in 20 cells from each depot/subject and averaged. To control for batch-tobatch staining variability, fluorescence intensity for each sample was normalized to the intensity of HAEC staining performed simultaneously. Data are expressed in arbitrary units (au) calculated by dividing the average fluorescence intensity of the subject sample by the intensity of the HAEC sample 9100, as previously described and validated. 28, 29 Confocal microscopy for primary endothelial cells was performed for FSP27 and VEGF-A (using Leica Sp5 (Leica microsystem, Buffalo Grove, IL) with an 963 oil immersion objective. Images were processed using Image J.
For 3-dimensional (3D) immunohistochemistry images of fibroblasts (which do not express any endogenous FSP27), we exposed cells to rFSP27 for 2 hours and performed 3-dimensional immunohistochemistry using standard measures. Immunostaining was performed using anti-FSP27 polyclonal antibodies followed by labeling with the fluorescent secondary antibody. Labeled cells were washed 3 times with PBS and mounted on slides in media with DAPI (Vector Laboratories). Confocal microscopy was performed using Nikon A1Rsi confocal microscope (Tokyo, Japan) with a 9100 oil immersion objective. Z-Slices of 0.3-lm thickness were captured from top to bottom of the nucleus. The 3-dimensional image was constructed from the Z-slices using Nikon software.
Adenovirus Transduction in Primary Endothelial Cells
Overexpression of human FSP27-HA-tagged adenovirus was performed as described previously. 20 Briefly, adenovirus, either control or adenovirus overexpressing FSP27, was added at a multiplicity of infection of 100 to primary endothelial cells isolated from visceral fat from obese subjects, Cells were grown for 48 hours under both experimental conditions, serum starved for 5 hours, stimulated with 100-nmol/L insulin for 30 minutes and then processed for NO production as described below.
Endothelial Cell Nitric Oxide Production
Endothelial NO production was measured using a sensitive and specific fluorescent probe by utilizing the membrane permeable probe 4,5-diaminofluorescein diacetate (DAF-2DA, Enzo, Framingdale, NY) as described previously. 29 Briefly, isolated endothelial cells were grown for 1 to 2 days, and either FSP27-overexpressed or -silenced for 48 hours. Cells were then serum starved and subsequently treated with vehicle (control) or 100-nmol/L insulin and NO probe DAF-2DA for 30-minutes. For the last 10 minutes of the experiment, Hoechst (Molecular probes, Grand Island, NY) was added for nuclear staining. Slides were imaged using a fluorescent microscope (920 magnification, Nikon Eclipse TE2000-E) and digital images were captured using a Photometric CoolSnap HQ2 Camera (Photometrics, Tucson, AZ). Exposure time was kept constant and fluorescent intensity (corrected for background fluorescence) was quantified by NIS Elements AR Software (Nikon Instruments Inc, Melville, NY) as described above.
Western Immunoblot Analyses
Proteins were extracted from adipose tissue by homogenization in liquid nitrogen. Ice-cold 1X lysis buffer (Cell Signaling, Danvers, MA) supplemented with protease inhibitor cocktail and phosphatase inhibitor II and III (Sigma Aldrich, St. Louis, MO) were added. For cell culture samples, including macrophages (human peripheral blood macrophages, Stemcell technologies, MA), ice-cold lysis buffer with inhibitors were directly added to cells. All samples were assayed for protein content using Bradford's method. Thirty-five micrograms of protein was subjected to electrophoresis in SDSpolyacrylamide gel under reducing conditions and blotted to a nitrocellulose membrane using the Bio-Rad Transblot Turbo Transfer system. For co-immunoprecipitation (co-IP) 500 lg of protein was incubated with antibody overnight, washed with PBS and ran immunoblot as described above. The membranes were blocked in 5% bovine serum albumin 0.1% Tween-20 in TBS for 1 hour at room temperature, and then incubated overnight at 4°C with primary anti-human antibodies (1:500-1000). Membranes were then washed off using TBS and incubated with horseradish peroxidase-conjugated secondary anti-rabbit IgG (R&D System, Minneapolis, MN) for 1 hour at room temperature, immune complexes were detected with the enhanced chemiluminescence ECL detection system (Bio-Rad). Densitometric analysis of bands was performed using ImageQuant TM LAS 4000 biomolecular imaging system (GE Healthcare, Pittsburg, PA). Proteins of interests were FSP27 (Catalogue #PA5-30793, Thermofisher); p-eNOS at serine 1177 (Catalogue #ab184154, Abcam); pAKT (protein kinase B) at serine 473 (Catalogue #44-609G, Thermofisher); VEGF-A (Catalogue #PA5-16754, Thermofisher), and GAPDH as a loading control. Intensity of bands for each protein was normalized to control band GAPDH.
In Vitro Transcription and Translation co-IP Immunoblot Assays
In vitro transcription and translation constructs were generated following the guidelines of Pierce's polymerase chain reaction (PCR) protocol for generating optimized templates. A 600-bp T7-IRES-Kozak sequence containing a T7 promoter, internal ribosome entry site, and Kozak sequence was amplified from pT7CFE1 vectors (Catalogue #88860, Pierce) with T7 sense and Kozak anti-sense primers. Next, an overlap sense primer (overlap with Kozak sequence) and an overlap anti-sense primer (overlap with gene ORF or fragments) containing a 30-nt poly-A sequence were used to amplify the gene ORF or gene fragment of FSP27 and VEGF-A. These 2 fragments were combined for overlap extension PCR with T7 sense and overlap anti-sense primers. PCR cycles were performed according to the guidelines. The resulting PCR templates were purified, and the identities of the templates were confirmed by restriction enzyme analysis. One-microgram of template DNA was used for 50-lL of transcriptiontranslation reaction mixture with a 1-Step Human Coupled IVT Kit according to manufacturer's recommendations (ThermoScientific). A sample without added DNA was used as a negative control; GFP (green fluorescent protein) template DNA was used as a positive control. Translation reaction time was optimized for protein length to reduce truncated proteins attributable to material exhaustion. Following translation, total protein concentration was calculated and small portions were subjected to Western blotting to confirm protein integrity or placed in À80°C storage for co-IP.
Angiogenic Sprout and Tube Formation Assays
For angiogenic sprout assays, fat-biopsy samples were collected at baseline and after weight-loss surgery. Samples were immediately placed in sterile endothelial basal media-2 (EBM-2, Lonza) and angiogenic capacity quantified as described previously. 30, 35 Briefly, fat samples were finely minced and digested with 1 mg/mL collagenase (Catalogue #LS004194, Worthington) for 30 minutes at 37°C. Digested tissue was passed through 100-lmol/L nylon filters, and washed in EBM-2 media. One mm 2 digested piece were embedded on ice cold 150-lL growth factor depleted matrigel (Catalogue #354230, BD Discovery) on a 48 well plate. The plate was incubated for 30 minutes in 37°C to let the matrigel polymerize. At the end of incubation, wells were covered with 500-lL of EBM-2 supplemented with growth factors and cultured at 37°C for 7 days. Half of the media was removed and replaced with fresh media every other day. Sprouts growing from the fat explants along the perimeter of each sample were counted under 9100 magnification by a masked investigator, as previously described. 35 For angiogenic tube formation assays, primary endothelial cells isolated from visceral fat were grown for 7 days in culture to generate enough cells numbers. On day 7 of culture, tube formation assay was performed according to protocol previously described (nature protocol 2010). 36 Briefly, cells were trypsinized and %5910 5 cells were plated in growth factor depleted gelled matrigel (polymerized) in duplicates. Cells were allowed to organize and coalesce into capillary-like structures for 6 hours with and without 100-nmol/L rFSP27. Branch formation was quantified according to company's quantification protocol (Chemicon/Invitrogen: angiogenic assay protocol) by counting each branch point formation per condition per subject.
Adipose VEGF-A Secretion
Visceral fat was incubated with and without human rFSP27 for 24 hours in serum-free media (0.5%, described above). For subcutaneous fat, tissue was subjected to either control or FSP27 siRNA for 48 hours as previously described. 29 Media were collected from all experimental conditions and VEGF-A concentration measured using an ELISA kit from R&D system (Catalogue # DVE00), and expressed as picograms of VEGF-A in milliliters of media, per milligrams of total protein in tissue.
Gene Expression
Immediately following adipose tissue collection, tissue samples were stored in RNAlater (Sigma-Aldrich) solution at À80°C. Total RNAs were isolated from homogenized whole adipose tissues using the QIAzol reagent and RNeasy Mini kits (Qiagen). RNA (0.5-1.5 lg) was retrotranscribed with High Capacity cDNA Synthesis Kits (Life Technologies). Quantitative real-time PCR reactions were performed using TaqMan gene expression assays in a ViiA7 PCR system (Life Technologies). Results were analyzed with the ΔΔCt method using GAPDH as a reference.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 6.0 software unless otherwise mentioned. Clinical characteristics of subjects were presented as meanAESD or percentage. Differences in clinical characteristics and adipose tissue gene expression between baseline and follow-up visits were examined using Student paired t tests. Interdepot differences in FSP27 expression, eNOS and AKT activation, and VEGF-A production were analyzed with Student paired t tests. Differences in tube formation angiogenesis were analyzed with Student paired t tests.
Repeated measures ANOVA was used to compare vascular response to rFSP27 treatments. Four-group differences in NO production were analyzed using ANOVA. Area under the curve of the plot for cumulative angiogenic growth (quantified as capillary sprout count) over the time period of 7 days was examined with Origin v6.1. Spearman correlation analysis was performed to examine associations between FSP27 gene expression and angiogenic capacity. Statistical significance was defined as P<0.05.
Results
Clinical Characteristics
A total of 61 subjects undergoing planned bariatric surgery were recruited for the study, each providing paired subcutaneous and visceral adipose tissue samples at baseline which were partitioned for different experiments. Clinical characteristics of all subjects are displayed in Table 1 and are consistent with those of the bariatric population at our medical center. For the longitudinal component, we followed a subset of subjects for up to 12 months (range 4-15 months) after bariatric surgery and their clinical characteristics are displayed in Table 2 . 
FSP27 Protein Expression in Primary Endothelial Cells
Using cellular immunofluorescence, we observed significantly lower FSP27 protein expression (red signal) in endothelial cells isolated from visceral versus subcutaneous depots ( Figure 1A and 1B, n=14, P<0.01).
FSP27 Modulates Insulin-Mediated Vasodilation
We have previously shown that insulin-mediated endothelium dependent vasodilation in arterioles isolated from visceral fat is impaired compared with arterioles from subcutaneous fat in human obesity. 33 Consequently, we examined insulinmediated vasomotor function of arterioles isolated from visceral fat, with and without human recombinant FSP27 (rFSP27) treatment in paired samples from each subject. We established an optimal dose of rFSP27 for arterioles by performing dose response experiments (data not displayed). Exposing arterioles to 5-nmol/L rFSP27 for an hour significantly improved insulin-mediated vasodilation (Figure 2 , n=10, P<0.01). Endothelium-independent vasodilation in response to papavarine was intact, and the positive response was nearly abolished by eNOS inhibitor N w -nitro-L-arginine methyl ester (L-NAME, 300-lmol/L) suggesting that the beneficial mechanism was related primarily to improved endothelial NO bioaction.
Recombinant Human FSP27 Improves InsulinMediated Activation of eNOS
To build on our observation in Figure 2 , we exposed visceral fat to rFSP27 (100-nmol/L) and examined insulin-mediated AKT and eNOS activation at serine 473 and 1177, respectively. As shown in Figure 3A through 3C (n=10, P<0.05), rFSP27 significantly increased insulin-mediated AKT and eNOS activation, suggesting that FSP27 modulates vascular function, in part, by augmenting eNOS bioaction.
Overexpression of FSP27 Improves Nitric Oxide Production
We overexpressed human FSP27, for the first time to our knowledge, in human primary endothelial cells isolated from visceral fat using an adenoviral transfer method. As shown in Figure 4A , using an adenoviral vector fusion construct that specifically overexpressed FSP27 intracellularly, we were able to increase cellular FSP27 protein expression by >2-fold as measured by immunofluorescence. This significantly increased insulin-mediated NO production, as measured by 
Inhibition of FSP27 Via siRNA Impairs InsulinMediated Activation of eNOS and Nitric Oxide Production
Conversely, we silenced FSP27 using siRNA (%50%-60% reduction) in subcutaneous fat from paired samples where visceral fat was used in experiments for Figure 3A through 3C. To support our findings, FSP27 silencing had the opposite effect and impaired insulin-mediated activation of eNOS and AKT ( Figure 5A through 5C, n=10, P<0.05). Additionally, we inhibited FSP27 in cultured HAECs and expectedly observed actions opposite to rFSP27 in primary cells. As displayed in Figure S1A and S1B, biological inhibition of FSP27 impaired insulin-mediated NO production ( Figure S1A n=3, P<0.01, Figure S1B n=3, P<0.05).
FSP27 Modulates Angiogenesis
We then explored whether FSP27 influences broader functions of blood vessels beyond vasodilation and focused on angiogenesis. We and others have shown that the visceral depot of obese humans display defective angiogenesis 35, 37 which has been linked to insulin resistance. 29 We used a method of angiogenic assessment involving a tube formation assay that quantifies the capacity of endothelial cells to organize and coalesce into capillary-like structures forming a rudimentary lumen within hours. 36 As shown in Figure 6A and 6B (n=7, P<0.05), isolated primary endothelial cells from obese subjects from the visceral depot exhibited weak vasculogenic behavior (control), whereas rFSP27 significantly improved channel formation at 6 hours. Correspondingly, we repeated these experiments with siRNA-mediated inhibition of FSP27 in HAECs which decreased the capacity of endothelial cells to form capillary-like structures ( Figure S1C , n=3, P<0.01).
FSP27 Regulates Vascular Function Via VEGF-A
To understand the mechanism of a potential cell autonomous action of FSP27 on vascular function, we considered a potential role of vascular endothelial growth factor-A (VEGF-A), a master regulator of neovascularization, and also stimulus for nitric oxide synthesis and release. 38, 39 We probed for an interaction between FSP27 and VEGF-A using co-immunoprecipitation and found an interaction between the 2 proteins ( Figure 7A ). In vitro transcription and translation co-IP immunoblot assay confirmed direct interaction of FSP27 and VEGF-A ( Figure 7B ), suggesting a functional relationship between these proteins. Further, using cultured HAECs we knocked-down FSP27 using siRNA, and measured VEGF-A protein to determine whether alteration in FSP27 modulates it. As displayed in Figure 7C , FSP27 silencing nearly abolished VEGF-A expression, and both proteins co-localized in primary endothelial cells isolated from human fat ( Figure S2 ). Additionally, we found that exposure of visceral fat to rFSP27 (100-nmol/L) for 24 hours significantly increased adipose tissue VEGF-A elaboration ( Figure S3A , n=11, P<0.01), while knockdown of FSP27 in subcutaneous fat reduced VEGF-A secretion ( Figure S3B , n=10, P<0.01). Our observation of reduced VEGF-A elaboration rather than complete shutdown in fat with FSP27 knockdown is likely attributed to VEGF-A production from other cell lines such as macrophages not under FSP27 regulatory control. To support this, as depicted in Figure S4 , we observed abundant VEGF-A in cultured human macrophages but absence of FSP27. These data suggest that FSP27 bioaction in endothelial cells may be regulated via control of VEGF-A. Moreover, to explore the mode of action of rFSP27 at the cellular level, we exposed cultured fibroblast (which do not express any endogenous FSP27) to rFSP27 for 2 hours and performed 3-dimensional immunohistochemistry. As shown in Figure S5 , exogenous rFSP27 enters and localizes internally in the cytosol rather than organizing around the cell membrane, suggesting that mode of bioaction of FSP27 may not be through cell surface receptors. 
Effect of Weight Loss on FSP27
We explored the effects of bariatric surgery on FSP27 gene expression and adipose microvascular vascular function. A subset of subjects (n=7) who participated in the follow-up study were followed longitudinally for up to 12AE3 months after the operation and provided subcutaneous biopsy samples after 30% weight loss. Their characteristics are displayed in Table 2 . Following Representative images of primary endothelial cells isolated from visceral fat that exhibited increased angiogenic branch formation when exposed to rFSP27 (recombinant FSP27) compared with control. B, Quantification of in-vitro angiogenic capacity of primary endothelial, cells with and without rFSP27 treatment for up to 6 hours (n=7, P<0.05). rFSP27 indicates recombinant fat-specific protein 27. *indicates statistical significance, such as P < 0.05.
extensive weight loss, angiogenic capacity of blood vessels in the subcutaneous depot significantly increased ( Figure 8A , n=7, P<0.05). In the same-paired samples, we observed parallel upregulation of FSP27 mRNA expression ( Figure 8B , n=7, P<0.05), which correlated positively with capillary sprouting despite the relatively small sample (r=0.79, P<0.05).
Discussion
In the present study, we identified to our knowledge for the first time, FSP27 as a novel regulator of vascular function that is downregulated in association with visceral obesity. We used several complementary approaches harnessing physiological studies of vascular insulin resistance, endothelial vasodilator function, and angiogenesis in live microvessels, as well as gain-and-loss of function biological methods exclusively using human samples to characterize the central role of FSP27 in the control of vascular phenotype. Specifically, recombinant FSP27 and/or targeted adenoviral endothelial FSP27 overexpression increased eNOS phosphorylation, NO production, and rescued defective angiogenic and vasodilator responses in dysfunctional human microvessels. Conversely, FSP27 siRNA-blunted insulin-mediated AKT/eNOS activation and impaired angiogenesis. Additionally, we observed that surgical weight loss bolstered adipose tissue FSP27 expression and augmented angiogenic capacity. From a mechanistic standpoint, we identified FSP27 as a previously unrecognized modulator of VEGF-A, a master regulator of angiogenesis and stimulus for NO production. 38, 39 Strikingly, FSP27 silencing in endothelial cells nearly fully abolished VEGF-A expression, and its knock-down in whole adipose tissue reduced VEGF-A elaboration. Collectively, these data strongly support a key role and functional significance of FSP27 as an endogenous modulator of vascular function in human obesity that has not been previously described that may play a key role in the pathogenesis of vascular disease. It had been generally considered that FSP27 functions primarily as a regulator of lipolysis in adipocytes and hence its designation as a "fat specific" protein. The existing literature exclusively describes its functions in relationship to metabolism, with experimental models showing that FSP27 deletion augments basal lipolysis and promotes insulin-resistance and hepatosteatosis under high-fat diet conditions. 23 Overexpression of FSP27 in human adipocytes protects from fatty acid induced insulin resistance, whereas its silencing impairs insulin-stimulated activation of AKT. 19 A major finding of our study is the discovery of FSP27 in vascular endothelial cells that is quantifiable and its expression downregulated in endothelial cells isolated from visceral compared with subcutaneous fat depots. We previously demonstrated that the visceral microenvironment is associated with several microvascular perturbations linked to vasodilator dysfunction and defective angiogenesis. 29, 33, 35 Clinically, accumulation of visceral fat has been most closely linked to the development of cardiometabolic disease and while underlying mechanisms are not fully understood, adipose tissue dysfunction and overproduction of pro-atherogenic adipocytokines has been a leading hypothesis. Among a large cadre of candidate mediators that have been put forth, FSP27 may be unique as it regulates insulin sensitivity and is differentially expressed in both adipocytes and endothelial cells in varying adipose depots and under conditions of obesogenic stress. While adipocyte FSP27 deficiency could negatively impact the vasculature by stimulating free fatty acid induced lipotoxicity, our data suggest that FSP27 also has distinct cell autonomous functions in endothelial cells. Recent studies demonstrate endothelial presence of lipid droplets as well as trans-differentiation with adipocytes; however, their cellular functions are not well known. [40] [41] [42] [43] In this regard, we demonstrated that FSP27 modulation in endothelial cells produced striking changes in their phenotype. We considered the role of VEGF-A since we identified a direct interaction between FSP27 and VEGF-A by in vitro transcription and translation, and VEGF-A is known to exert control over angiogenesis and NO-dependent processes. 38, 39, 44 Modulation of FSP27 bioaction, either by rFSP27 or siRNA, induced changes in VEGF-A secretion from human adipose tissue, and siRNA knockdown of FSP27 in cultured endothelial cells induced a profound decrease in VEGF-A protein expression. Within the adipose microenvironment, adipocytes, and macrophages are likely the major sources of VEGF-A. 45, 46 We did not observe any significant FSP27 expression in cultured human macrophages which supports our finding that adipose FSP27 silencing in fat did not completely shut off VEGF production. Animal models of FSP27 47 or VEGF-A knockout 48 induce directionally similar metabolic abnormalities and insulin resistance. FSP27 may regulate VEGF-A at several stages including transcription translation as we observed changes in VEGF-A protein within 24 hours of FSP27 modulation (both with rFSP27 and siRNA), or potentially direct effects as vasomotor function improved rapidly with rFSP27 exposure.
In the present study, we also explored the role of bariatric surgery in a subset of subjects that provided repeat adipose tissue after profound weight loss. Bariatric surgery has emerged as an effective treatment for obesity and its cardiometabolic comorbidities, as it improves cardiac risk factors, remits diabetes mellitus, and improves long-term total and cardiovascular mortality. [49] [50] [51] [52] The effect of weight change on FSP27 are limited, as gene expression in the liver fell, 53 while increased in subcutaneous fat with weight loss. 54 We similarly observed FSP27 upregulation in human fat after 30% weight loss that was correlated with increased angiogenic sprouting in adipose tissue explants. The clinical importance of increased angiogenic capacity in human fat is an open question; however, capillary rarefaction and local tissue pseudo-hypoxia have been linked to mechanisms of adipose tissue dysfunction locally, 55 and consequently whole-body metabolic dysfunction. Our current study has several limitations. First, our study consists of severely obese subjects undergoing bariatric surgery, with a relatively small sample size in some experiments, and findings may not be applicable to individuals with milder degrees of obesity. Second, the experimental set-up involved ex vivo manipulations that may not fully recapitulate in vivo conditions. Third, the majority of study populations were women, which reflects general clinical practice and known sex differences in population that seek weight loss treatments. Fourth, many of our findings are in adipose tissue microvessels and may not necessarily apply to the systemic vasculature which merits further investigation. However, this is counterbalanced by our work with primary tissue from living subjects that brings high translational value. We also emphasize that our ability to directly access human samples and examine live dysfunctional blood vessels within minutes after surgical biopsy provides us with major opportunities to discover novel regulatory networks. Mechanisms learned from the fat microenvironment could have clinical impact and provide translational clues to systemic disease or drugable targets. Adipose arteriolar function correlates with systemic endothelial function, cerebrovascular responses, and tracks cardiovascular risk factors. 56 Fifth, while we explored regulation of VEGF-A by direct interaction with FSP27, the mode of action of FSP27 has not been fully elucidated and mapping out binding domains of these proteins was beyond the scope of the current paper that will be a focus of our future studies. Lastly, follow-up biopsies were limited to subcutaneous fat depots since these were the only reachable sites without requiring repeat surgery for visceral access that could not be justified for solely research purposes.
Conclusions
In conclusion, we believe we have identified a previously unrecognized, and important regulator of arteriolar vasomotor function and angiogenesis. Obesity-related downregulation of FSP27 may link obesity to cardiometabolic risk. Further studies are needed to provide functional frameworks to understand the unique features of FSP27 signaling and it pathological impact on the human vascular system. 
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